Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pancreatin versus placebo for pancreatic exocrine insufficiency in unresectable pancreatic cancer
ACTRN12611001172998Phase 4Not yet recruiting
- Sponsor
- Dr. Anna McLiesh
- Start
- Dec 2011
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Blood Coagulation Factors → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Insulin and Analogs → Hormones & Growth Factors → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in exocrine pancreatic insufficiency (EPI) comparing Pancreatin treatment with Placebo (2 arms). Primary endpoint: Weight change. Planned start Dec 2011; status: not yet recruiting.
02
Drugs
pancreatin
03
Conditions
exocrine pancreatic insufficiency (EPI)
Beyond the preview
Go deeper on ACTRN12611001172998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611001172998.